CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
The information set forth under this Item 2.02. Results of
Operations and Financial Condition, including the exhibit
attached hereto, shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended,
nor shall it be deemed incorporated by reference into any filing
under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.
Attached as Exhibit 99.1 is a copy of a press release of Cyclacel
Pharmaceuticals, Inc. (the Company), dated May
11, 2017, announcing certain financial results for the first
quarter ended March 31, 2017.
The Company will conduct a conference call to review its
financial results on May 11, 2017, at 4:30 p.m., Eastern Time.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number | Description | |
| 99.1 |
Press release announcing financial results for the first quarter ended March 31, 2017, dated May 11, 2017. |
About CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC)
Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors. CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC) Recent Trading Information
CYCLACEL PHARMACEUTICALS, INC. (NASDAQ:CYCC) closed its last trading session up +0.19 at 5.30 with 30,828 shares trading hands.
